

## ASX Announcement

### Roadshow investor webinar with Professor Yuman Fong

---

**Sydney, Australia, 18 July 2023:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar on Friday 21 July 2023 at 11am AEST with Managing Director and CEO Leslie Chong, who will be joined by CF33 co-inventor Professor Yuman Fong.

The webinar is being conducted as part of a non-deal investor roadshow, which includes Professor Fong being the keynote speaker at this year's Bioshares Biotech Summit.

Please register for the webinar at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_n78krTj0REuFQvpiguvsuQ](https://us02web.zoom.us/webinar/register/WN_n78krTj0REuFQvpiguvsuQ)

Investors are encouraged to send questions prior to the webinar to  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link shortly after the conclusion of the session.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)

**Media Enquiries**  
Matt Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter and Instagram @TeamImugene  
Like us on Facebook @Imugene



Connect with us on LinkedIn @Imugene Limited  
View us on YouTube @Imugene Limited

## **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*